Rallybio Corporation.
RLYB.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. The company focuses on developing product candidates for hematologic diseases, immuno-inflammation, and ...Show More
Better Health for All
0
No evidence available to assess Rallybio Corporation on Better Health for All.
Fair Money & Economic Opportunity
0
Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for rare diseases.
1
Its core business does not involve lending, insuring, moving, or storing money, nor does it offer financial products or services to consumers.
2
Therefore, all KPIs related to financial services, such as customer segments, pricing, fees, lending compliance, wealth building outcomes, and financial literacy initiatives, are not applicable to the company's operations.
Fair Pay & Worker Respect
0
No evidence available to assess Rallybio Corporation on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Rallybio Corporation on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
Rallybio has a comprehensive whistleblower policy with an anonymous hotline, ensuring confidential submissions and explicitly stating no retaliation for good faith reports.
1
Concerns are delivered to the General Counsel and the Chair of the Audit Committee.
2
The company has not had any financial restatements in the past five years, and its clawback policy addresses erroneously-awarded incentive compensation in the event of an accounting restatement.
3
More than 80% of Rallybio’s Board of Directors are independent, and a Director Conflict of Interest Policy is in place to manage potential conflicts.
4
Rallybio has adopted policies on Anti-Bribery and Anti-Corruption, referencing the U.S. Foreign Corrupt Practices Act (FCPA) and PhRMA's Code on Interactions with Healthcare Professionals.
5
However, the extent of independent verification of ethical claims is limited, with third-party consultants primarily used for executive and director compensation analysis, GxP vendor audits, and information security risk assessments, rather than comprehensive ethical claims.
6
Kind to Animals
-70
Rallybio Corporation conducts animal testing, with an expectation to report additional animal data for its RLYB331 program in the first half of 2024.
1
The company utilizes a novel preclinical mouse model of FNAIT and purchases WT BALB/c female mice from Charles River Laboratories.
2
All animal protocols are carried out in compliance with US Department of Health and Human Services guidelines and the National Institutes of Health Guide for the Care and Use of Laboratory Animals, indicating a vague policy with ongoing testing.
3
The company's R&D comprised nearly 60% of operating expenses in both 2021 and 2022, but less than 1% of this budget is explicitly stated to support animal-free technologies.
4
Rallybio participates in partnerships with companies like Exscientia and AbCellera for drug discovery, but these collaborations are not explicitly focused on developing animal-free testing methods or standards.
5
The company is an active participant in local, state, and industry organizations, but there is no evidence of a public position or advocacy for animal welfare legislation.
6
No War, No Weapons
0
The provided articles describe Rallybio Corporation as a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases.
1
The information primarily covers financial updates, R&D pipeline, corporate governance, and general ESG initiatives. None of the articles contain specific, concrete data points or mentions related to arms manufacturing, military contracts, dual-use technology with military applications, sales to embargoed regimes, peacebuilding investments, conflict divestment policies, or any other metrics relevant to the 'No War, No Weapons' ethical value. Therefore, no KPIs under this value can be scored based on the evidence provided.
Planet-Friendly Business
0
No evidence available to assess Rallybio Corporation on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points or facts were found in the provided articles regarding Rallybio Corporation's performance on any of the KPIs related to 'Respect for Cultures & Communities'.
1
The articles primarily discuss financial transactions or research and development efforts, and explicitly state a lack of information concerning community engagement or cultural respect practices.
2
Safe & Smart Tech
-30
The company's privacy policy does not document any data breaches or incidents of unauthorized data use.
1
However, user data control is significantly limited, with users only able to opt-out of email communications and manage cookies through browser settings, lacking broader data management or deletion options.
2
Data minimization practices are also poor, as comments are retained indefinitely, and the policy does not specify retention periods for other collected data.
3
While the company states it discloses data to comply with legal obligations, including FDA reporting, there is no explicit mention of compliance with major privacy regulations such as GDPR or CCPA.
4
Zero Waste & Sustainable Products
-40
Rallybio has implemented several waste reduction initiatives, including the standard practice of electronic material use, double-sided printing, in-office recycling of paper, cans, and bottles, and providing a SodaStream as an alternative to canned beverages.
1
For hazardous waste management, the company partners with UConn TIP for battery recycling from office and home.
2